Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coral LaboratoriesBOM:524506 72 Operating Margin % is 21.38% as of Mar. 2026, which is 44% above its 10-year median of 14.89. GuruFocus rates BOM:524506 with a GF Score™ of 72/100 and a GF Value™ of ₹483.47 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 958 Drug Manufacturers companies, Coral Laboratories ranks better than 71.61% on this metric.
Coral Laboratories Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Coral Laboratories's Operating Margin % or its related term are showing as below:
BOM:524506'
s Operating Margin % Range Over the Past 10 Years
Min: 2.09 Med: 14.89 Max: 23.84
Current: 15.23
BOM:524506's Operating Margin % is ranked better than 71.61% of 958
companies
in the Drug Manufacturers industry
Industry Median: 7.275
vs BOM:524506: 15.23
Coral Laboratories's 5-Year Average Operating Margin % Growth Rate was 15.60% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Coral Laboratories Operating Margin % Related Terms
Coral Laboratories Operating Margin % Historical Data
* Premium members only.
The historical data trend for Coral Laboratories's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Coral Laboratories's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coral Laboratories Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Coral Laboratories's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Coral Laboratories's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Coral Laboratories's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coral Laboratories (BOM:524506) has a Operating Margin % of 21.38% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Coral Laboratories and its competitors. This is 44% above median its historical median of 14.89. Over the past decade, Coral Laboratories' Operating Margin % has ranged from 2.09 to 23.84. According to the industry distribution chart, Coral Laboratories ranks #272 out of 958 companies in the Drug Manufacturers industry, placing it in the top 28.4%.
Is Coral Laboratories' Operating Margin % too high?
Coral Laboratories' current Operating Margin % of 21.38% is 44% above median its 10-year median of 14.89. Over the past 10 years, this metric has ranged from a low of 2.09 to a high of 23.84. The Drug Manufacturers industry median Operating Margin % is 7.28. Coral Laboratories' value of 21.38% is 193.9% above this industry median. Based on the distribution chart, Coral Laboratories ranks #272 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Coral Laboratories has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coral Laboratories' Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Coral Laboratories ranks #272 out of 958 companies for Operating Margin %. This puts Coral Laboratories in the upper half of its industry. The industry median Operating Margin % is 7.28. Coral Laboratories' value of 21.38% is 193.9% above this benchmark. Historically, Coral Laboratories' own Operating Margin % has ranged from 2.09 to 23.84 over the past decade. While the company's 10-year median is 14.89 vs. the industry median of 7.28, Coral Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.28, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coral Laboratories's current Operating Margin % of 21.38% is 193.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Coral Laboratories and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coral Laboratories's current Operating Margin % is 21.38%, which is 44% above median its own 10-year median of 14.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coral Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Coral Laboratories (BOM:524506) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹483.47, compared to a current price of ₹577.90 — trading 19.5% above its estimated fair value. The current Operating Margin % is 21.38%, which is 44% above median its 10-year median of 14.89 and 193.9% above the Drug Manufacturers industry median of 7.28. Coral Laboratories' overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Coral Laboratories (BOM:524506), the current Operating Margin % is 21.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coral Laboratories (BOM:524506) Overvalued in 2026?
Based on GuruFocus' analysis, Coral Laboratories stock appears to be overvalued.
The current stock price of ₹577.90 is trading 19.5% above its estimated GF Value™ of ₹483.47.
GuruFocus considers Coral Laboratories to be Modestly Overvalued.
Key valuation signals for BOM:524506:
Operating Margin %: 21.38% (44% above median its 10-year median of 14.89)
GF Value™: ₹483.47 vs. price of ₹577.90 (19.5% above fair value)
Industry Position: 193.9% above the Drug Manufacturers median (#272 of 958)
No single metric tells the full story. See the BOM:524506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coral Laboratories Ltd is engaged in the pharmaceutical business. The company is involved in the formulation of medicines. The company's dosage form includes tablets, capsules, liquid orals, b-lactam, dry syrup, meter dose inhalers, injectables, drops, sprays, special kits, and others. Its geographical segments include Ethiopia, India, and the Rest of the world.
72GF Score
Get the complete analysis for BOM:524506
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524506 has been successfully added to your 
